ELISA kit Activating transcription factor 1,Atf1,cAMP-dependent transcription factor ATF-1,Cyclic AMP-dependent transcription factor ATF-1,Mouse,Mus musculus,TCR-ATF1
- Known as:
- Enzyme-linked immunosorbent assay test reagent Activating transcription factor 1,Atf1,cAMP-dependent transcription factor ATF-1,Cyclic AMP-dependent transcription factor ATF-1,Mouse,Mus musculus,TCR-ATF1
- Catalog number:
- E1346m
- Product Quantity:
- 96T
- Category:
- -
- Supplier:
- EIAab
- Gene target:
- ELISA kit Activating transcription factor 1 Atf1 cAMP-dependent ATF-1 Cyclic AMP-dependent Mouse Mus musculus TCR-ATF1
Related genes to: ELISA kit Activating transcription factor 1,Atf1,cAMP-dependent transcription factor ATF-1,Cyclic AMP-dependent transcription factor ATF-1,Mouse,Mus musculus,TCR-ATF1
- Gene:
- ATF1 NIH gene
- Name:
- activating transcription factor 1
- Previous symbol:
- -
- Synonyms:
- TREB36
- Chromosome:
- 12q13.12
- Locus Type:
- gene with protein product
- Date approved:
- 1994-03-16
- Date modifiied:
- 2016-10-05
- Gene:
- BATF NIH gene
- Name:
- basic leucine zipper ATF-like transcription factor
- Previous symbol:
- -
- Synonyms:
- B-ATF, SFA-2, BATF1
- Chromosome:
- 14q24.3
- Locus Type:
- gene with protein product
- Date approved:
- 2000-05-15
- Date modifiied:
- 2016-10-05
- Gene:
- DIDO1 NIH gene
- Name:
- death inducer-obliterator 1
- Previous symbol:
- C20orf158, DATF1
- Synonyms:
- DIO1, dJ885L7.8, FLJ11265, KIAA0333, DIO-1, BYE1
- Chromosome:
- 20q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1999-12-17
- Date modifiied:
- 2014-11-19
- Gene:
- GDNF NIH gene
- Name:
- glial cell derived neurotrophic factor
- Previous symbol:
- -
- Synonyms:
- ATF1, ATF2, HFB1-GDNF
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-04
- Date modifiied:
- 2016-10-05
- Gene:
- IGHMBP2 NIH gene
- Name:
- immunoglobulin mu DNA binding protein 2
- Previous symbol:
- -
- Synonyms:
- ZFAND7, SMUBP2, CATF1, SMARD1, HCSA, HMN6, CMT2S
- Chromosome:
- 11q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1994-12-15
- Date modifiied:
- 2019-04-23
Related products to: ELISA kit Activating transcription factor 1,Atf1,cAMP-dependent transcription factor ATF-1,Cyclic AMP-dependent transcription factor ATF-1,Mouse,Mus musculus,TCR-ATF1
Related articles to: ELISA kit Activating transcription factor 1,Atf1,cAMP-dependent transcription factor ATF-1,Cyclic AMP-dependent transcription factor ATF-1,Mouse,Mus musculus,TCR-ATF1
- Nox1 signaling is a causal key element in arterial hypertension. Recently, we identified protein disulfide isomerase A1 (PDI) as a novel regulatory protein that regulates Nox1 signaling in VSMCs. Spontaneously hypertensive rats (SHR) have increased levels of PDI in mesenteric resistance arteries compared with Wistar controls; however, its consequences remain unclear. Herein, we investigated the role of PDI in mediating Nox1 transcriptional upregulation and its effects on vascular dysfunction in hypertension. We demonstrate that PDI contributes to the development of hypertension via enhanced transcriptional upregulation of Nox1 in vascular smooth muscle cells (VSMCs). We show for the first time that PDI sulfenylation by hydrogen peroxide contributes to EGFR activation in hypertension via increased shedding of epidermal growth factor-like ligands. PDI also increases intracellular calcium levels, and contractile responses induced by ANG II. PDI silencing or pharmacological inhibition in VSMCs significantly decreases EGFR activation and Nox1 transcription. Overexpression of PDI in VSMCs enhances ANG II-induced EGFR activation and ATF1 translocation to the nucleus. Mechanistically, PDI increases ATF1-induced Nox1 transcription and enhances the contractile responses to ANG II. Herein we show that ATF1 binding to Nox1 transcription putative regulatory regions is augmented by PDI. Altogether, we provide evidence that HB-EGF in SHR resistance vessels promotes the nuclear translocation of ATF1, under the control of PDI, and thereby induces Nox1 gene expression and increases vascular reactivity. Thus, PDI acts as a thiol redox-dependent enhancer of vascular dysfunction in hypertension and could represent a novel therapeutic target for the treatment of this disease. - Source: PubMed
Publication date: 2024/03/01
Camargo Livia De LuccaTrevelin Silvia Celloneda Silva Guilherme Henrique GattiDos Santos Dias Ana AliceOliveira Maria AparecidaMikhaylichenko OlgaAndrowiki Aline C DDos Santos Celio XavierHolbrook Lisa-MarieCeravolo Graziela ScaliantiDenadai-Souza AlexandreRibeiro Izabela Martina RamosSartoretto SimoneLaurindo Francisco Rafael MartinsColtri Patricia PereiraAntunes Vagner RobertoTouyz RhianMiller Francis JShah Ajay MLopes Lucia Rossetti - To investigate the clinical application of EWSR1 gene rearrangement by fluorescence in situ hybridization (FISH) in bone and soft tissue tumors and to analyze the cases with atypical signal pattern. The cases detected for EWSR1 gene rearrangement by FISH in Beijing Jishuitan Hospital, Capital Medical University from 2014 to 2021 were collected, and the value of detecting EWSR1 gene rearrangement for diagnosing bone and soft tissue tumors was analyzed. The cases with atypical positive signals were further analyzed by next generation sequencing (NGS). FISH using EWSR1 break-apart probe kit was successfully performed in 97% (205/211) of cases, 6 cases failed. Four of the 6 failures were due to improper decalcification, 1 case due to signal overlap caused by thick slices, and 1 case due to signal amplification and disorder. EWSR1 gene rearrangements were positive in 122 cases (122/205, 59%), atypical positive signal in 8 cases (8/205, 4%), and negative in 75 cases (75/205, 37%). In cases testing positive, the percentage of positive cells ranged from 34% to 98%, with 120 cases (120/122, 98%) showing a positive cell percentage greater than 50%. Among the 205 successfully tested cases, 156 cases were histologically diagnosed as Ewing's sarcoma, of which 110 were positive (110/156, 71%), 7 were atypical positive (7/156, 4%), and 39 were negative (39/156, 25%). Nine cases were histologically diagnosed as clear cell sarcoma of soft tissue, of which 6 were positive (6/9), 1 was atypical positive (1/9), and 2 were negative (2/9). Five cases were histologically diagnosed as extraskeletal myxoid chondrosarcoma, of which 2 were positive (2/5) and 3 were negative (3/5). Three cases were histologically diagnosed as angiomatoid fibrous histiocytoma, of which 2 were positive (2/3) and 1 was negative (1/3). Two cases were histologically diagnosed as myoepithelioma of soft tissue, of which 1 was positive (1/2) and 1 was negative (1/2). One case was histologically diagnosed as olfactory neuroblastoma with a positive result. The 29 other tumor cases including osteosarcoma, synovial sarcoma, and malignant melanoma and others were all negative. Basing on histology as the standard for diagnosis and considering atypical positive cases as negative, comparing with the 29 cases of other tumors as control group, the sensitivity for diagnosing Ewing's sarcoma through the detection of EWSR1 gene rearrangement was 71%, and the specificity was 100%; the sensitivity for diagnosing clear cell sarcoma of soft tissue was 67%, and the specificity was 100%; the sensitivity for diagnosing extraskeletal myxoid chondrosarcoma was 40%, and the specificity was 100%; the sensitivity for diagnosing angiomatoid fibrous histiocytoma was 67%, and the specificity was 100%; the sensitivity for diagnosing myoepithelioma of soft tissue was 50%, and the specificity was 100%; the sensitivity for diagnosing olfactory neuroblastoma was 100%, and the specificity was 100%. Four of 8 cases with atypical positive signals analyzed by NGS showed EWSR1 rearrangement, including EWSR1::FLI1 in one case of Ewing sarcoma, EWSR1::NFATC2 in one case of EWSR1::NFATC2-rearranged sarcoma, EWSR1::ATF1 in one case of clear cell sarcoma of soft tissue and EWSR1::NR4A3 in one case of extraskeletal myxoid chondrosarcoma. Detection of EWSR1 rearrangement by FISH is of utmost significance in the diagnosis of bone and soft tissue tumors. Cases with atypical positive signals should be further scrutinized, correlating with their histomorphology and verifying by NGS if necessary. - Source: PubMed
Li LZhang MZhang T TDing Y - Periodontitis is a chronic inflammatory disease resulting from bacterial plaque infection. While the involvement of activating transcription factor 1 (ATF1) has been extensively explored in various human diseases, its specific role in periodontitis remains unclear. This study aims to elucidate the expression and biological function of ATF1 in the context of periodontitis. - Source: PubMed
Guo WeiYan ShuyunZhao Ge - To review tumors identified as "clear cell sarcoma" in order to determine similarities to the rare EWS fusion positive jaw and salivary gland tumors clear cell odontogenic carcinoma (CCOC) and clear cell carcinoma of the salivary gland (CCC). - Source: PubMed
Publication date: 2024/03/25
Xhori OrnelaDeol NavkiranRivera Camron MZavras JasonWeil Sophia GZafari HiradThierauf Julia CFaquin William CChoy EdwinRivera Miguel NJohn Iafrate AJaquinet AlexandreTroulis Maria J - Bone and soft tissue tumors (BST) are a highly heterogeneous group largely classified by their line of differentiation, based on their resemblance to their normal counterpart in adult tissue. Yet, rendering a specific diagnosis can be challenging, primarily due to their rarity and overlapping histopathologic features or clinical presentations. Over the past few decades, seemingly histogenetic-specific gene fusions/translocations and amplifications have been discovered, aiding in a more nuanced classification, leading to well-established objective diagnostic criteria and the development of specific surrogate ancillary tests targeting these genetic aberrations (e.g., immunohistochemistry). Ironically, the same research also has revealed that some specific tumor subtypes may be the result of differing and often multiple gene fusions/translocations, but, more interestingly, identical gene fusions may be present in more than one phenotypically and biologically distinct neoplasm, sometimes with entirely different clinical behavior. Prime examples include, EWSR1::ATF1 and, less commonly, EWSR1::CREB1 gene fusions present in both clear cell sarcoma, a malignant high-grade tumor with melanocytic differentiation, and angiomatoid fibrous histiocytoma, a mesenchymal neoplasm of intermediate malignancy with a generally indolent course. Similarly, MDM2 amplification, once deemed to be pathognomonic for atypical lipomatous tumor/well differentiated and dedifferentiated liposarcoma, has been documented in a range of additional distinct tumors, including low grade osteosarcomas (e.g. low grade central and surface parosteal) and high-grade intimal sarcomas, amongst others. Such findings reinforce the importance of careful attention to morphological and clinicoradiological features and correlation with molecular testing before rendering a specific diagnosis. Future classification systems in BST neoplasms cannot be solely based on molecular events and ideally will balance morphologic features with molecular analysis. Herein, we provide a narrative literature review of the more common BST neoplasms with shared genetic events but differing demographics, morphology, immunophenotype, and clinical behavior, re-emphasizing the importance of the hematoxylin and eosin slide and the "eye" of the practicing pathologist. - Source: PubMed
Publication date: 2024/03/21
Dashti Nooshin KSchukow Casey PKilpatrick Scott E